Medable, Pluto Health Strike Enterprise Partnership
Collaboration to focus on accelerating clinical development and increase access to research.
Medable Inc. announced in a company press release that it has formed a partnership with Pluto Health, a smart care coordination services company. Combining Pluto Health’s health coordination platform and Medable’s digitally enabled clinical trials platform, the joint venture aims to providing patients with greater control and the ability to share their health data directly into clinical trials through a seamless integration.
“Our partnership is primarily a win for patients, alongside other stakeholders, who will benefit from ongoing enhanced support,” said Joy Bhosai, MD, PhD, CEO, founder, Pluto Health, in a company press release. “Pluto is passionate about improving patient care in communities and designing systems that deliver resources for patients to manage health needs over time, especially if they are going through a clinical trial as part of a care option. We are excited for what the future holds with Medable.”
Reference: Medable Partners with Pluto Health to Optimize Patient Experience and Improve Access to Clinical Trials. Business Wire. October 3, 2023. Accessed October 3, 2023. https://www.businesswire.com/news/home/20231003413736/en/Medable-Partners-with-Pluto-Health-to-Optimize-Patient-Experience-and-Improve-Access-to-Clinical-Trials
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
